Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus

Resolve Therapeutics is a privately held biotechnology company that is dedicated to improving the lives of patients with lupus and Sjögren’s syndrome through the development of its platform of targeted nuclease therapeutics.  In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus, Sjogrens syndrome and other autoimmune diseases.  Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital.  For more information on the company please visit:  https://www.resolvebio.com.
Contact:
James Posada, Ph.D.
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 727-7010
jp@resolvebio.com
Logo – https://photos.prnewswire.com/prnh/20160210/331815LOGO
 
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/resolve-therapeutics-announces-publication-of-clinical-data-demonstrating-the-role-of-circulating-rna-in-systemic-lupus-erythematosus-300316369.html
SOURCE Resolve Therapeutics, LLC

Related Links

https://www.resolvebio.com